Her science background helps her predict whether or not drugs will win approval and she's able to judge the riskrewardprofile based upon the current midstage clinical study.
Bottom line: If, consistent with our base-case expectation, the U.S. averts a recession, equities are inexpensive enough to provide investors with an attractive risk-reward profile.
In other words, we needed entry and exit and position-size methodologies that would allow us to skew the risk-reward profile, that would allow us to end up with a larger magnitude of profits than losses.